Skip to main
CORT

Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics (CORT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 0%
Sell 20%
Strong Sell 0%

Bulls say

Corcept Therapeutics is well-positioned to see continued success and growth in the coming years due to its strong product pipeline, recent NDA resubmission for relacorilant, and successful pharmacy transition for their flagship product Korlym. Financially, the company's strong sales growth in Korlym and early physician adoption of their recently approved drug, Lifyroli, suggest potential for significant revenue growth in the future. Risks to this outlook include potential issues with commercialization and regulatory approval, as well as any potential legal or intellectual property challenges.

Bears say

Corcept Therapeutics is facing potential challenges as its current flagship product Korlym, which accounts for the majority of its revenue, approaches generic competition in 2024. Additionally, its pipeline compounds are still in clinical trials and may not see success in the market, leading to limited future revenue growth. This, coupled with the fact that the company has a history of high operating expenses and net losses, paints a negative outlook for its stock.

Corcept Therapeutics (CORT) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corcept Therapeutics (CORT) Forecast

Analysts have given Corcept Therapeutics (CORT) a Buy based on their latest research and market trends.

According to 5 analysts, Corcept Therapeutics (CORT) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $122.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $122.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corcept Therapeutics (CORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.